FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4289916338> ?p ?o ?g. }

• W4289916338 endingPage "LBA1001" @default.
• W4289916338 startingPage "LBA1001" @default.
• W4289916338 abstract "LBA1001 Background: HR+/HER2– disease is the most common subtype of metastatic breast cancer (MBC). Treatment includes sequential endocrine therapy combined with targeted agents followed by single-agent chemotherapy, with increasingly shorter durations of benefit. SG is an anti–Trop-2 antibody-drug conjugate approved for metastatic triple-negative breast cancer with ≥2 prior therapies (≥1 for MBC). The HR+/HER2– MBC cohort of the phase 1/2 IMMU-132-01 study (n = 54) had an objective response rate (ORR) of 31.5%, median progression-free survival (PFS) of 5.5 mo, median overall survival (OS) of 12 mo, and a manageable safety profile with SG. TROPiCS-02 is a phase 3 randomized study (NCT03901339) to confirm SG outcomes in HR+/HER2– advanced breast cancer. Methods: Adults with locally determined, HR+/HER2– unresectable locally advanced or MBC, ECOG performance status of 0 or 1, and 2-4 prior chemotherapy regimens for MBC were eligible; 1 prior therapy for MBC was allowed if disease progressed ≤12 mo after (neo)adjuvant therapy. Pts must have received ≥1 prior taxane, CDK4/6 inhibitor, and endocrine therapy in any setting. Pts were randomized 1:1 to receive SG (10 mg/kg IV on d1 and 8, every 21d) or TPC (capecitabine, eribulin, vinorelbine, or gemcitabine) until disease progression/unacceptable toxicity. Primary endpoint was PFS per RECIST v1.1 by blinded independent central review (final analysis) with key secondary endpoint of OS (1 st planned interim analysis). Results: At data cutoff on Jan 3, 2022, 272 vs 271 pts were randomized to receive SG vs TPC, respectively. Pt characteristics in the SG vs TPC arms were similar (3 median prior chemotherapy regimens for MBC [range, 0-8]; 95% had visceral metastases, 86% had prior endocrine therapy for MBC for ≥6 mo, 60% and 38% received prior CDK4/6 inhibitors for ≤12 and > 12 mo, respectively). SG (vs TPC) improved median PFS (5.5 vs 4.0 mo; HR, 0.66; 95% CI, 0.53-0.83; P= 0.0003); PFS rates at 6 and 12 mo were 46% vs 30% and 21% vs 7%, respectively. SG vs TPC showed a numeric but nonsignificant difference in OS (13.9 vs 12.3 mo; HR, 0.84; P= 0.143); ORR (21% vs 14%) and clinical benefit rate (34% vs 22%) were higher with SG vs TPC and median duration of response was 7.4 vs 5.6 mo, respectively. Overall, 74% vs 60% of patients (SG vs TPC) had grade ≥3 treatment-emergent adverse events (AEs); neutropenia (51% vs 39%) and diarrhea (10% vs 1%) were most common. AEs leading to discontinuation of SG vs TPC were low (6% vs 4%). There was 1 treatment-related death in the SG arm; none in the TPC arm. Conclusions: SG had a statistically significant, clinically meaningful PFS benefit over single-agent chemotherapy and a manageable safety profile in pts with heavily pre-treated HR+/HER2– endocrine-resistant, unresectable locally advanced or MBC, who have limited treatment options. Clinical trial information: NCT03901339." @default.
• W4289916338 created "2022-08-06" @default.
• W4289916338 creator A5011232197 @default.
• W4289916338 creator A5020487290 @default.
• W4289916338 creator A5022846357 @default.
• W4289916338 creator A5034765349 @default.
• W4289916338 creator A5034972183 @default.
• W4289916338 creator A5037708639 @default.
• W4289916338 creator A5042743608 @default.
• W4289916338 creator A5051629490 @default.
• W4289916338 creator A5056490796 @default.
• W4289916338 creator A5058791215 @default.
• W4289916338 creator A5059225417 @default.
• W4289916338 creator A5061026190 @default.
• W4289916338 creator A5069056507 @default.
• W4289916338 creator A5083899821 @default.
• W4289916338 creator A5089555041 @default.
• W4289916338 creator A5090188675 @default.
• W4289916338 date "2022-06-10" @default.
• W4289916338 modified "2023-10-18" @default.
• W4289916338 title "Primary results from TROPiCS-02: A randomized phase 3 study of sacituzumab govitecan (SG) versus treatment of physician’s choice (TPC) in patients (Pts) with hormone receptor–positive/HER2-negative (HR+/HER2-) advanced breast cancer." @default.
• W4289916338 doi "https://doi.org/10.1200/jco.2022.40.17_suppl.lba1001" @default.
• W4289916338 hasPublicationYear "2022" @default.
• W4289916338 type Work @default.
• W4289916338 citedByCount "57" @default.
• W4289916338 countsByYear W42899163382022 @default.
• W4289916338 countsByYear W42899163382023 @default.
• W4289916338 crossrefType "journal-article" @default.
• W4289916338 hasAuthorship W4289916338A5011232197 @default.
• W4289916338 hasAuthorship W4289916338A5020487290 @default.
• W4289916338 hasAuthorship W4289916338A5022846357 @default.
• W4289916338 hasAuthorship W4289916338A5034765349 @default.
• W4289916338 hasAuthorship W4289916338A5034972183 @default.
• W4289916338 hasAuthorship W4289916338A5037708639 @default.
• W4289916338 hasAuthorship W4289916338A5042743608 @default.
• W4289916338 hasAuthorship W4289916338A5051629490 @default.
• W4289916338 hasAuthorship W4289916338A5056490796 @default.
• W4289916338 hasAuthorship W4289916338A5058791215 @default.
• W4289916338 hasAuthorship W4289916338A5059225417 @default.
• W4289916338 hasAuthorship W4289916338A5061026190 @default.
• W4289916338 hasAuthorship W4289916338A5069056507 @default.
• W4289916338 hasAuthorship W4289916338A5083899821 @default.
• W4289916338 hasAuthorship W4289916338A5089555041 @default.
• W4289916338 hasAuthorship W4289916338A5090188675 @default.
• W4289916338 hasConcept C121608353 @default.
• W4289916338 hasConcept C126322002 @default.
• W4289916338 hasConcept C141071460 @default.
• W4289916338 hasConcept C143998085 @default.
• W4289916338 hasConcept C168563851 @default.
• W4289916338 hasConcept C203092338 @default.
• W4289916338 hasConcept C2775930923 @default.
• W4289916338 hasConcept C2776387010 @default.
• W4289916338 hasConcept C2776694085 @default.
• W4289916338 hasConcept C2777511904 @default.
• W4289916338 hasConcept C2778239845 @default.
• W4289916338 hasConcept C2780258809 @default.
• W4289916338 hasConcept C2780350996 @default.
• W4289916338 hasConcept C2780739268 @default.
• W4289916338 hasConcept C530470458 @default.
• W4289916338 hasConcept C61943457 @default.
• W4289916338 hasConcept C71924100 @default.
• W4289916338 hasConceptScore W4289916338C121608353 @default.
• W4289916338 hasConceptScore W4289916338C126322002 @default.
• W4289916338 hasConceptScore W4289916338C141071460 @default.
• W4289916338 hasConceptScore W4289916338C143998085 @default.
• W4289916338 hasConceptScore W4289916338C168563851 @default.
• W4289916338 hasConceptScore W4289916338C203092338 @default.
• W4289916338 hasConceptScore W4289916338C2775930923 @default.
• W4289916338 hasConceptScore W4289916338C2776387010 @default.
• W4289916338 hasConceptScore W4289916338C2776694085 @default.
• W4289916338 hasConceptScore W4289916338C2777511904 @default.
• W4289916338 hasConceptScore W4289916338C2778239845 @default.
• W4289916338 hasConceptScore W4289916338C2780258809 @default.
• W4289916338 hasConceptScore W4289916338C2780350996 @default.
• W4289916338 hasConceptScore W4289916338C2780739268 @default.
• W4289916338 hasConceptScore W4289916338C530470458 @default.
• W4289916338 hasConceptScore W4289916338C61943457 @default.
• W4289916338 hasConceptScore W4289916338C71924100 @default.
• W4289916338 hasFunder F4320308573 @default.
• W4289916338 hasIssue "17_suppl" @default.
• W4289916338 hasLocation W42899163381 @default.
• W4289916338 hasOpenAccess W4289916338 @default.
• W4289916338 hasPrimaryLocation W42899163381 @default.
• W4289916338 hasRelatedWork W1999778859 @default.
• W4289916338 hasRelatedWork W2288325587 @default.
• W4289916338 hasRelatedWork W2309523645 @default.
• W4289916338 hasRelatedWork W2388022328 @default.
• W4289916338 hasRelatedWork W2598750857 @default.
• W4289916338 hasRelatedWork W2622893994 @default.
• W4289916338 hasRelatedWork W4233933635 @default.
• W4289916338 hasRelatedWork W4289916338 @default.
• W4289916338 hasRelatedWork W4295837360 @default.
• W4289916338 hasRelatedWork W4322773979 @default.
• W4289916338 hasVolume "40" @default.
• W4289916338 isParatext "false" @default.
• W4289916338 isRetracted "false" @default.
• W4289916338 workType "article" @default.